Kornimate/medical-research-clean huggingface dataset:
truncal blocks versus wound infiltration for sicd

Conditions: Intraoperative Pain; Postoperative Pain

Summary: this is a single-center, randomized and prospective trial of all patients undergoing s-icd implantation. subjects will only be eligible for this study if they are ≥ 18 years of age and eligible to undergo s-icd implant at mount sinai morningside hospital. they will be randomized to receive either surgical infiltration of local anesthetic or truncal blocks. intraoperative and postoperative data will be collected including total opioid use, pain scores postprocedure, total postoperative narcotic need and length of stay.

this is a single-center, randomized and prospective trial of all patients undergoing s-icd implantation. subjects will only be eligible for this study if they are ≥ 18 years of age and eligible to undergo s-icd implant at mount sinai morningside hospital. they will be randomized to receive either surgical infiltration of local anesthetic or truncal blocks. intraoperative and postoperative data will be collected including total opioid use, pain scores postprocedure, total postoperative narcotic need and length of stay. the procedures involved for the study are the placement of the described truncal blocks or wound infiltration. data to be collected are patient demographics, history of present illness, past medical history, and pain management techniques required (i.e non-narcotics and narcotics use). in addition, age, race, gender and bmi will also be collected. intraoperative analgesia requirements, postoperative analgesia requirements, duration of procedure and length of stay will also be collected.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * patients undergoing s-icd placement exclusion criteria: * allergy to amide local anesthetics

Keywords: subcutaneous implantable cardioverter-defibrillators (s-icd) truncal blocks
a non-therapeutic feasibility study of the radioligand [11c]-ucb-j for imaging synaptic density

Conditions: Healthy; Alzheimer Disease

Summary: up to 20 subjects will receive an injection with \[11c\]-ucb-j followed by a pet scan on days 1 and 28

after assessing eligibility during a 4-week screening period, approximately 20 subjects will participate in the pet acquisition phase of the study. drop-outs or unevaluable subjects will be replaced for a target sample size of 20 completed and evaluable subjects. during the screening period, a 3d t1-weighted mri must be acquired and reviewed for exclusion criteria and acquisition quality. on the day of radioligand administration (day 1), subjects will come to the study center for an ambulatory visit (visit 1). after re-confirming eligibility, all subjects will receive an injection with \[11c\]-ucb-j followed by a pet scan. using an arterial line and manual sampling, blood samples will be collected up to 90 minutes after radioligand injection in order to quantify radioactivity concentration in whole blood and plasma as well as parent fraction over time. subjects will return to the clinic for one more ambulatory visit on day 28 ± 3 (visit 2). the same procedures will be performed as on day 1. pet scanning duration will be initially set to 90 minutes. after a minimum of 4 subjects have completed baseline and day 28 scans, 90 minute and 60 minute scan data will be analyzed. based on this analysis, and at the discretion of the investigator, it will be decided whether the remaining subjects will require 60 or 90 minute scans. adverse events will be recorded throughout the study.

Eligibility criteria:
inclusion criteria: group 1 * healthy male or female age 55 - 75 years old, inclusive, at the time of informed consent. * mini-mental state examination (mmse) greater than or equal to 27. group 2 * adult males or females age 55 - 75 years old, inclusive, at the time of informed consent. * confirmed diagnosis of mild-to-moderate ad, defined as: 1. national institute on aging - alzheimer's association (nia-aa) "probable" diagnosis (see appendix 2); 2. mmse 18-26. exclusion criteria: * history or current evidence of any clinically significant cardiovascular, endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic (with the exception of ad in group 2), psychiatric, renal, or other major disease, as determined by the investigator.
acupuncture therapy combined with breathing training for patients with stroke complicated

Conditions: Stroke; Lung Diseases

Summary: the goal of this prospective randomized controlled study is to explore the clinical efficacy of acupuncture therapy combined with breathing training in patients with stroke complicated with pulmonary infection. the intervention group and control group were treated with conventional drug therapy, rehabilitation therapy and breathing training for 2 consecutive weeks. on this basis, the intervention group additionally received acupuncture therapy. to evaluate the clinical efficacy of both groups.

to explore the clinical efficacy of acupuncture therapy combined with breathing training in patients with stroke complicated with pulmonary infection. using a prospective randomized controlled study, 72 patients with pulmonary infection after stroke admitted to our hospital from may 2020 to may 2021 were randomly divided into the intervention group and control group, with 36 patients in each group. both groups were treated with conventional drug therapy, rehabilitation therapy and breathing training for 2 consecutive weeks. on this basis, the intervention group additionally received acupuncture therapy. the traditional chinese medicine (tcm) syndrome score and clinical pulmonary infection score (cpis) before and after treatment, time of fever relieving, time for the disappearance of cough, expectoration and moist rales in the lung, white blood cell count (wbc), serum c-reactive protein (crp) level, calcitonin (pct) level and pulmonary indexes were compared between the 2 groups, respectively, to evaluate clinical efficacy.

Eligibility criteria:
inclusion criteria: * meeting the diagnostic criteria of western medicine for stroke complicated with pneumonia * conforming to the tcm syndrome of vital qi deficiency and phlegm-heat obstructing the lung * confirmed as the initial onset of stroke through ct or magnetic resonance imaging (mri) * clear consciousness, no cognitive impairment, and ability to cooperate with pulmonary function assessment and rehabilitation training * willingness to participate in this study and sign the informed consent exclusion criteria: * patients with systemic multi-organ failure such as the heart, brain, kidney, etc * patients with a coronary metal stent or pacemaker implantation * patients with malignant tumors * patients with severe cognitive impairment, depression or mental disorders * patients with pulmonary infections before stroke or caused by other causes * patients in the acute phase of infection

Keywords: acupuncture therapy respiratory training seroinflammatory factors lung function
metformin for the treatment of endometrial hyperplasia

Conditions: Endometrial Hyperplasia; Endometrial Hyperplasia Without Atypia

Summary: the purpose of this study is to see if metformin will be effective in making endometrial hyperplasia without atypia better by returning the tissue to a normal state.

this is a multi-institutional pilot clinical trial designed to estimate the response rate and safety of metformin for the treatment of simple and complex endometrial hyperplasia (eh) without atypia. enrollment of patients will occur at unc-chapel hill and southern pines women's health center. fifteen patients will be enrolled over the course of 1 year. metformin will be initiated at 850 mg orally once daily, and titrated up to twice daily over a minimum of 1 months time. treatment will last 12 weeks and then patients will undergo repeat endometrial biopsy to assess for regression or persistence of eh.

Eligibility criteria:
inclusion criteria: * be between the ages of 18-75 years old * have a confirmed diagnosis of endometrial hyperplasia without atypia based upon endometrial biopsy * have no contraindications to short-term metformin therapy * have a creatinine clearance of ≥ 90 ml/min, as calculated by the cockroft-gault formula * have normal serum transaminase values (ast and alt) * need to be able to undergo metformin treatment for a duration of 12 weeks prior to repeat endometrial biopsy exclusion criteria: * are currently taking metformin or have taken metformin in the past 6 months or have a history of an allergic reaction or intolerance at any time to metformin * have a history of liver or renal dysfunction. * have a random glucose of ≤ 65 or ≥ 200 * have a recent history of alcoholism. former alcoholics who have abstained from alcohol for 5 years or more may be enrolled in this study. * have a history of vitamin b12 deficiency * are pregnant * are currently taking insulin * are taking a drug that may significantly interact or influence the metabolism of metformin * in the opinion of the investigator, the patient is felt not to be appropriate for the study

Keywords: endometrial hyperplasia uterus pilot metformin
evaluating the effectiveness of a multi-level health-related social needs initiative

Conditions: Type 2 Diabetes; Hypertension; Hyperlipidemia; Health-related Social Problems

Summary: the goal of this study is to evaluate the effectiveness of a multi-level health-related social needs (hrsn) initiative among adult patients diagnosed with type 2 diabetes, plus hypertension or hyperlipidemia. the multi-level initiative includes hrsn data collection, training and tools for health care professionals, care coordinator support, and community resources. patients with type 2 diabetes plus hypertension or hyperlipidemia will be screened for hrsn as part of the primary care clinic intake process to assess if patients have any social needs (like difficulty with getting food, housing, or transportation). if patients screen positive for having social needs, then patients will be offered support, which can include help from primary care providers with adjusting a patient's disease management plan, referrals to care coordinators to provide additional assistance in addressing social needs, and information about community organizations that offer resources for social needs. the initiative will be integrated as a system change across vumc adult primary care practices. the investigators will use a prospective, single-arm clinical trial to evaluate effects on clinical outcomes for 12 months. data will be extracted from the ehr on adult patients diagnosed with type 2 diabetes, and either hypertension or hyperlipidemia. the investigators hypothesize that the initiative will reduce the impact of hrsn on clinical outcomes over the study period. the investigators will also administer surveys to a subgroup of patients to examine trends in self-reported psychosocial and behavioral measures over the course of the initiative.


Eligibility criteria:
eligibility criteria for ehr data extraction inclusion criteria: * 18 years of age or older * completed the health-related social needs (hrsn) screener as part of a primary care visit * diagnosed with type 2 diabetes, plus hypertension and/or hyperlipidemia as reflected by icd-10 billing codes * receive care at one of six partner vanderbilt university medical center primary care clinics: south one hundred oaks, north one hundred oaks, green hills, hillsboro medical group, melrose, bellevue eligibility criteria for patient surveys (subset of ehr data) inclusion criteria: * 18 years of age or older * completed the hrsn screener as part of a primary care visit * diagnosed with type 2 diabetes, plus hypertension and/or hyperlipidemia as reflected by icd-10 billing codes * receive care at one of six partner vanderbilt university medical center primary care clinics: south one hundred oaks, north one hundred oaks, green hills, hillsboro medical group, melrose, bellevue * english-speaking exclusion criteria: * blindness * hearing impairment * conditions that would interfere with survey completion (e.g., significant dementia, active psychosis or mania) * being near the end of life (hospice or home hospice)
study to treat uveitis associated macular edema

Conditions: Cystoid Macular Edema; Uveitis

Summary: the purpose of this study is to determine whether denufosol tetrasodium (ins37217) intravitreal injection is well tolerated and has the potential to treat uveitis associated macular edema.

denufosol tetrasodium (ins37217) intravitreal injection may provide clinical benefit in treatment of uveitis associated macular edema (ume) by reducing retinal thickness as measured by oct and possibly enabling recovery of vision loss associated with ume. denufosol tetrasodium may also reverse the fluid accumulation of ume.

Eligibility criteria:
inclusion criteria: * have anterior uveitis, intermediate uveitis, posterior uveitis or panuveitis in at least one eye * have persistent macular edema and uveitis whose conditions are stable * have no change in medication regimen for at least 3 months prior to randomization if currently taking medications such as immunosuppressive or anti-inflammatory agents; steroidal or non-steroidal agents (drops, oral or injected) * have an oct scan with a qualifying retinal thickness in the study eye * have evidence of macular edema on oct scan * have at lease one eligible eye to be treated in the study based on visual acuity. exclusion criteria: * have proliferative vitreoretinopathy greater than grade b * have subretinal or vitreous hemorrhage, corneal opacity, or other conditions, which limit the view of the retina or obscure fa * have uncontrollable elevated iop, advanced, previous filtration surgery, or any current evidence of endophthalmitis in the study eye * have ocular disorders in the study eye that may confound interpretation of study results * have had cataract surgery in the study eye within 3 months, yag laser capsulotomy within the past 1 month, or any other intraocular surgery within the past 90 days * have pre-operative spherical equivalent refractive error of more than -10 diopters of myopia in the study eye * have had any intravitreal or periocular injection or corticosteroids in the study eye during the 3 months prior to screening * have any ocular implant device for the delivery of therapeutic agents to the eye * be taking any excluded medications that could obscure or confound study results

Keywords: uveitis macular edema uveitis associated macular edema
comparison of fasting blood glucose measurements from fingertip and intravenous on patient satisfaction in patients with diabetes mellitus

Conditions: Diabetes Mellitus

Summary: the study was designed as a randomized controlled experimental study in order to compare the fasting blood glucose values measured by puncturing the fingertips and using the intravenous route of patients diagnosed with diabetes mellitus, and to determine the effect on patient satisfaction. the blood glucose measurement via the intravenous catheter has an effect on increasing the comfort of the patient compared to the fingertip measurement. it is thought that information can be provided to increase patient satisfaction.


Eligibility criteria:
inclusion criteria: * 18 years and older * no advanced hearing and vision problems * able to speak and understand turkish * easy to communicate * literate * agreeing to participate in the research voluntarily * patients who are hospitalized * regular finger blood sugar monitoring, * patients with an intravenous vascular access date within the first 24 hours * patients who had been diagnosed with type 2 diabetes mellitus for at least one year were. exclusion criteria: * those who are treated with sedative drugs * patients using antipsychotic medication * patients with continuous drug infusion through the intravenous line * patients whose intravenous vascular access date has passed 24 hours * patients in unconscious, confused, apathetic state

Keywords: diabetes mellitus fear of finger piercing patient satisfaction blood glucose measurement
effectiveness of targeted cognitive training for neurological deficits in people with schizophrenia

Conditions: Schizophrenia

Summary: this study will determine the effectiveness of reward-intensive, computer-based targeted cognitive training in improving neurocognitive deficits in people with schizophrenia.

schizophrenia is a chronic brain disorder that causes severe disability. it is characterized by psychotic symptoms, including hallucinations and delusions. neurocognitive deficits, such as impaired neurocognitive processing efficiency, also affect people with schizophrenia. this deficiency in the speed and accuracy with which the brain perceives and responds to targets causes scrambled messages to be transmitted in the brain, thereby affecting executive control and memory. medications are available that effectively treat the psychotic symptoms. the neurocognitive deficits, however, do not subside with medication treatment, and are responsible for the failure to improve the e their psychosocial functioning of people with schizophrenia, even after their psychotic symptoms have gone into remission. the targeted cognitive training (tct) exercises in this study are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets. this study will determine the effectiveness of reward-intensive, computer-based tct in improving neurocognitive deficits in people with schizophrenia. participants in this double-blind study will be paired according to iq and baseline symptom severity. one member of each pair will be randomly assigned to training exercises that use tct. the other will be assigned to a control intervention, which will involve commercially available computer games. all participants will complete exercises with their assigned intervention for 1 hour per day, 5 days per week, until 90 hours of training has been accumulated. neuroimaging will be performed on a subgroup of participants to examine changes in brain activation patterns in response to the cognitive training. upon study completion and at the 6-month follow up visit, participants will be assessed for improvement in the following areas: cognitive performance; symptom profile; quality of life; and social cue recognition.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder * good general health * first language is english * clinically stable (i.e., no inpatient hospital stays for 3 months prior to study entry; on stable doses of medication) exclusion criteria: * history of substance abuse within 6 months prior to study entry * neurological disorder * any metal in the body, or claustrophobia

Keywords: schizoaffective disorder cognitive remediation fmri
validation of the french version of the sydney swallow questionnaire in patients with neuromuscular diseases

Conditions: Dysphagia; Neuromuscular Diseases

Summary: measurements of dysphagia severity are important when making management decisions and in the objective evaluation of swallowing impairments. the sydney swallow questionnaire (ssq) is a validated self-report inventory using a visual analogue scale. this questionnaire permits a quantitative, sensitive, specific, repeatable and easily responsive evaluation of dysphagia in different pathology. opposed to largely used videofluoroscopy swallowing study and endoscopy examinations, the ssq is noninvasive, less expensive, avoids radiation exposure and enables a readily available assessment. validated french version is not yet available. in the first phase of the study the investigators will validated this translation in dysphagic patients and control. secondly, the investigators will validate the ssq in neuromuscular patients.


Eligibility criteria:
inclusion criteria: phase 1: group 1: * healthy participants * able to speak, read and write in french * aged at least 18 years old group 2: * patients, with symptoms indicative of a deglutition disorder, referred for a videofluoroscopic study to the otolaryngology, head and neck surgery department, voice and swallowing clinic * able to speak, read and write in french * aged at least 18 years old phase 2: * clinical diagnosis of neuromuscular diseases * able to understand french exclusion criteria: phase 1: group 1: * history of neurological or neuromuscular disease * history of any diagnosticated swallowing disorder group 2: * patients who could not be cataloged as dysphagic or non-dysphagic after the videofluoroscopic study evaluation * patients unable to answer the questionnaire phase 2: * patients who could not be cataloged as dysphagic or non-dysphagic * patients unable to answer the questionnaire

Keywords: neuromuscular dysphagia swallowing disorders questionnaire assessment
non substitutive strategies to improve haemophilia care in developing countries. experience in ivory coast.

Conditions: Haemophilia; Developing Countries

Summary: this study aims to make an inventory of the condition and care of patients with haemophilia and carriers for haemophilia in ivory coast and to promote the use non substitutive strategies that are not costly and available in ivory coast, to improve the management of haemophilia in this country. the purpose of this project is to evaluate the extent to which the active promotion of these various measures will improve the care of patients with haemophilia and carriers in ivory coast.

1. establish a baseline of the condition of haemophilia in ivory coast (number of patients, demographics, reassessment of diagnosis, joint status...).(year 1) 2. develop tools to assess the intervention (eg transcultural validation of qol questionnaires, develop booklets to record bleedings...). (year 1) 3. intervention phase that will focus on education of patients and their family, education of caregivers, training of the laboratory to the diagnosis of haemophilia and promotion of non substitutive strategies to improve haemophilia care in ivory coast (ddavp, antifibrinolytics, physiotherapy, dental care,...). 4. follow-up phase during 2 years. 5. outcome analysis

Eligibility criteria:
inclusion criteria: * males with severe and moderate haemophilia a and b in ivory coast (any age). * females over 12 years who are carriers for severe and moderate haemophilia a and b in ivory coast. * exclusion criteria: subjects not willing to participate.

Keywords: haemophilia
epidemiological study to describe non-small-cell lung carcinoma (nsclc) clinical management patterns in mena. lung-epiclin/ ksa

Conditions: NSCLC Patient Characteristics

Summary: the study is to provide accurate, reliable information on nsclc clinical management across mena (middle east north africa) countries in order to detect unmet medical needs of this disease, it is a purely observational study; therefore patients are not assigned to a particular therapeutic strategy beforehand by a protocol. treatment will be according to current clinical practice.


Eligibility criteria:
inclusion criteria: * confirmed nsclc diagnosis (e.g. bronchoscope or fnab), all stages, men and women, attending the responsible department of treating this type of patients for the first time between april 1st 2011 and march 31 2012, for pro sub-sample: ability to read and write since they will be asked to participate in the pro part of the study. selection will not be based on the disease stage of each patient, in order to avoid a selection bias exclusion criteria: * according to the study design there will not be any exclusion criteria in order to provide a high validity and to obtain the most accurate real daily practice information.

Keywords: patient outcomes